107 related articles for article (PubMed ID: 25583353)
1. Modeling interactions between C₆₀ antiviral compounds and HIV protease.
Al Garalleh H; Thamwattana N; Cox BJ; Hill JM
Bull Math Biol; 2015 Jan; 77(1):184-201. PubMed ID: 25583353
[TBL] [Abstract][Full Text] [Related]
2. Receptor- and ligand-based study of fullerene analogues: comprehensive computational approach including quantum-chemical, QSAR and molecular docking simulations.
Ahmed L; Rasulev B; Turabekova M; Leszczynska D; Leszczynski J
Org Biomol Chem; 2013 Sep; 11(35):5798-808. PubMed ID: 23900343
[TBL] [Abstract][Full Text] [Related]
3. Target-selective photodegradation of HIV-1 protease and inhibition of HIV-1 replication in living cells by designed fullerene-sugar hybrids.
Tanimoto S; Sakai S; Kudo E; Okada S; Matsumura S; Takahashi D; Toshima K
Chem Asian J; 2012 May; 7(5):911-4. PubMed ID: 22378594
[No Abstract] [Full Text] [Related]
4. Molecular dynamics study of the connection between flap closing and binding of fullerene-based inhibitors of the HIV-1 protease.
Zhu Z; Schuster DI; Tuckerman ME
Biochemistry; 2003 Feb; 42(5):1326-33. PubMed ID: 12564936
[TBL] [Abstract][Full Text] [Related]
5. Binding of novel fullerene inhibitors to HIV-1 protease: insight through molecular dynamics and molecular mechanics Poisson-Boltzmann surface area calculations.
Tzoupis H; Leonis G; Durdagi S; Mouchlis V; Mavromoustakos T; Papadopoulos MG
J Comput Aided Mol Des; 2011 Oct; 25(10):959-76. PubMed ID: 21969102
[TBL] [Abstract][Full Text] [Related]
6. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
[TBL] [Abstract][Full Text] [Related]
7. SMILES-based optimal descriptors: QSAR analysis of fullerene-based HIV-1 PR inhibitors by means of balance of correlations.
Toropov AA; Toropova AP; Benfenati E; Leszczynska D; Leszczynski J
J Comput Chem; 2010 Jan; 31(2):381-92. PubMed ID: 19479738
[TBL] [Abstract][Full Text] [Related]
8. Deformation density components analysis of fullerene-based anti-HIV drugs.
Fakhraee S; Souri M
J Mol Model; 2014 Nov; 20(11):2486. PubMed ID: 25388278
[TBL] [Abstract][Full Text] [Related]
9. Structural and electronic properties of new fullerene derivatives and their possible application as HIV-1 protease inhibitors.
Ibrahim M; Saleh NA; Hameed AJ; Elshemey WM; Elsayed AA
Spectrochim Acta A Mol Biomol Spectrosc; 2010 Feb; 75(2):702-9. PubMed ID: 20044306
[TBL] [Abstract][Full Text] [Related]
10. Qualitative study of drug resistance in retroviral protease using structural modeling and site-directed mutagenesis.
Culberson JC; Bush BL; Sardana VV
Methods Enzymol; 1994; 241():385-94. PubMed ID: 7854190
[No Abstract] [Full Text] [Related]
11. Fullerene derivative as anti-HIV protease inhibitor: molecular modeling and QSAR approaches.
Ibrahim M; Saleh NA; Elshemey WM; Elsayed AA
Mini Rev Med Chem; 2012 Jun; 12(6):447-51. PubMed ID: 22587761
[TBL] [Abstract][Full Text] [Related]
12. Structural evidence for effectiveness of darunavir and two related antiviral inhibitors against HIV-2 protease.
Kovalevsky AY; Louis JM; Aniana A; Ghosh AK; Weber IT
J Mol Biol; 2008 Dec; 384(1):178-92. PubMed ID: 18834890
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
Skulnick HI; Johnson PD; Howe WJ; Tomich PK; Chong KT; Watenpaugh KD; Janakiraman MN; Dolak LA; McGrath JP; Lynn JC
J Med Chem; 1995 Dec; 38(26):4968-71. PubMed ID: 8544171
[No Abstract] [Full Text] [Related]
14. InChI-based optimal descriptors: QSAR analysis of fullerene[C60]-based HIV-1 PR inhibitors by correlation balance.
Toropov AA; Toropova AP; Benfenati E; Leszczynska D; Leszczynski J
Eur J Med Chem; 2010 Apr; 45(4):1387-94. PubMed ID: 20116899
[TBL] [Abstract][Full Text] [Related]
15. The QSAR and docking calculations of fullerene derivatives as HIV-1 protease inhibitors.
Saleh NA
Spectrochim Acta A Mol Biomol Spectrosc; 2015 Feb; 136 Pt C():1523-9. PubMed ID: 25459714
[TBL] [Abstract][Full Text] [Related]
16. Molecular Dynamics Simulation Study of the HIV-1 Protease Inhibit ion Using Fullerene and New Fullerene Derivatives of Carbon Nanostructures.
Barzegar A; Naghizadeh E; Zakariazadeh M; Azamat J
Mini Rev Med Chem; 2017; 17(7):633-647. PubMed ID: 27292780
[TBL] [Abstract][Full Text] [Related]
17. Enamino-oxindole HIV protease inhibitors.
Eissenstat M; Guerassina T; Gulnik S; Afonina E; Silva AM; Ludtke D; Yokoe H; Yu B; Erickson J
Bioorg Med Chem Lett; 2012 Aug; 22(15):5078-83. PubMed ID: 22749283
[TBL] [Abstract][Full Text] [Related]
18. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J
J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016
[TBL] [Abstract][Full Text] [Related]
19. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
Islam MA; Pillay TS
J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the HIV-1 and HIV-2 proteases by curcumin and curcumin boron complexes.
Sui Z; Salto R; Li J; Craik C; Ortiz de Montellano PR
Bioorg Med Chem; 1993 Dec; 1(6):415-22. PubMed ID: 8087563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
